In the United States,prostate cancer is the most prevalent noncutaneouscancer in men and the second most common cause of cancer deaths.1,2 Glutamate carboxypeptidase II, commonly known as prostate-specificmembrane antigen (PSMA), is an overexpressed cell surface enzyme onprostate cancer cells and a valuable clinical biomarker of prostatecancer.3 The recognition site is composedof two pockets with zinc ions, the nonpharmacophore pocket (S1) andthe glutamate-sensing pocket (S1′). Here, FOLH1 is linked to Familial prostate cancer.